141 related articles for article (PubMed ID: 30256865)
1. Different prelamin A forms accumulate in human fibroblasts: a study in experimental models and progeria.
Dominici S; Fiori V; Magnani M; Schena E; Capanni C; Camozzi D; D'Apice MR; Le Dour C; Auclair M; Caron M; Novelli G; Vigouroux C; Maraldi NM; Lattanzi G
Eur J Histochem; 2009 Mar; 53(1):e6. PubMed ID: 30256865
[TBL] [Abstract][Full Text] [Related]
2. Different prelamin A forms accumulate in human fibroblasts: a study in experimental models and progeria.
Dominici S; Fiori V; Magnani M; Schena E; Capanni C; Camozzi D; D'Apice MR; Le Dour C; Auclair M; Caron M; Novelli G; Vigouroux C; Maraldi NM; Lattanzi G
Eur J Histochem; 2009; 53(1):43-52. PubMed ID: 19351612
[TBL] [Abstract][Full Text] [Related]
3. The farnesyl transferase inhibitor (FTI) lonafarnib improves nuclear morphology in ZMPSTE24-deficient fibroblasts from patients with the progeroid disorder MAD-B.
Odinammadu KO; Shilagardi K; Tuminelli K; Judge DP; Gordon LB; Michaelis S
Nucleus; 2023 Dec; 14(1):2288476. PubMed ID: 38050983
[TBL] [Abstract][Full Text] [Related]
4. Drugs affecting prelamin A processing: effects on heterochromatin organization.
Mattioli E; Columbaro M; Capanni C; Santi S; Maraldi NM; D'Apice MR; Novelli G; Riccio M; Squarzoni S; Foisner R; Lattanzi G
Exp Cell Res; 2008 Feb; 314(3):453-62. PubMed ID: 18093584
[TBL] [Abstract][Full Text] [Related]
5. Blocking protein farnesyltransferase improves nuclear shape in fibroblasts from humans with progeroid syndromes.
Toth JI; Yang SH; Qiao X; Beigneux AP; Gelb MH; Moulson CL; Miner JH; Young SG; Fong LG
Proc Natl Acad Sci U S A; 2005 Sep; 102(36):12873-8. PubMed ID: 16129834
[TBL] [Abstract][Full Text] [Related]
6. Abolishing the prelamin A ZMPSTE24 cleavage site leads to progeroid phenotypes with near-normal longevity in mice.
Wang Y; Shilagardi K; Hsu T; Odinammadu KO; Maruyama T; Wu W; Lin CS; Damoci CB; Spear ED; Shin JY; Hsu W; Michaelis S; Worman HJ
Proc Natl Acad Sci U S A; 2022 Mar; 119(9):. PubMed ID: 35197292
[TBL] [Abstract][Full Text] [Related]
7. Autophagic degradation of farnesylated prelamin A as a therapeutic approach to lamin-linked progeria.
Cenni V; Capanni C; Columbaro M; Ortolani M; D'Apice MR; Novelli G; Fini M; Marmiroli S; Scarano E; Maraldi NM; Squarzoni S; Prencipe S; Lattanzi G
Eur J Histochem; 2011 Oct; 55(4):e36. PubMed ID: 22297442
[TBL] [Abstract][Full Text] [Related]
8. Lamin A precursor induces barrier-to-autointegration factor nuclear localization.
Capanni C; Cenni V; Haraguchi T; Squarzoni S; Schüchner S; Ogris E; Novelli G; Maraldi N; Lattanzi G
Cell Cycle; 2010 Jul; 9(13):2600-10. PubMed ID: 20581439
[TBL] [Abstract][Full Text] [Related]
9. A mutation abolishing the ZMPSTE24 cleavage site in prelamin A causes a progeroid disorder.
Wang Y; Lichter-Konecki U; Anyane-Yeboa K; Shaw JE; Lu JT; Östlund C; Shin JY; Clark LN; Gundersen GG; Nagy PL; Worman HJ
J Cell Sci; 2016 May; 129(10):1975-80. PubMed ID: 27034136
[TBL] [Abstract][Full Text] [Related]
10. Defining substrate requirements for cleavage of farnesylated prelamin A by the integral membrane zinc metalloprotease ZMPSTE24.
Wood KM; Spear ED; Mossberg OW; Odinammadu KO; Xu W; Michaelis S
PLoS One; 2020; 15(12):e0239269. PubMed ID: 33315887
[TBL] [Abstract][Full Text] [Related]
11. Effects of prelamin A processing inhibitors on the differentiation and activity of human osteoclasts.
Zini N; Avnet S; Ghisu S; Maraldi NM; Squarzoni S; Baldini N; Lattanzi G
J Cell Biochem; 2008 Sep; 105(1):34-40. PubMed ID: 18442054
[TBL] [Abstract][Full Text] [Related]
12. Emerin-prelamin A interplay in human fibroblasts.
Capanni C; Del Coco R; Mattioli E; Camozzi D; Columbaro M; Schena E; Merlini L; Squarzoni S; Maraldi NM; Lattanzi G
Biol Cell; 2009 Sep; 101(9):541-54. PubMed ID: 19323649
[TBL] [Abstract][Full Text] [Related]
13. A humanized yeast system to analyze cleavage of prelamin A by ZMPSTE24.
Spear ED; Alford RF; Babatz TD; Wood KM; Mossberg OW; Odinammadu K; Shilagardi K; Gray JJ; Michaelis S
Methods; 2019 Mar; 157():47-55. PubMed ID: 30625386
[TBL] [Abstract][Full Text] [Related]
14. Prelamin A, Zmpste24, misshapen cell nuclei, and progeria--new evidence suggesting that protein farnesylation could be important for disease pathogenesis.
Young SG; Fong LG; Michaelis S
J Lipid Res; 2005 Dec; 46(12):2531-58. PubMed ID: 16207929
[TBL] [Abstract][Full Text] [Related]
15. Prelamin A processing, accumulation and distribution in normal cells and laminopathy disorders.
Casasola A; Scalzo D; Nandakumar V; Halow J; Recillas-Targa F; Groudine M; Rincón-Arano H
Nucleus; 2016; 7(1):84-102. PubMed ID: 26900797
[TBL] [Abstract][Full Text] [Related]
16. HIV protease inhibitors block the zinc metalloproteinase ZMPSTE24 and lead to an accumulation of prelamin A in cells.
Coffinier C; Hudon SE; Farber EA; Chang SY; Hrycyna CA; Young SG; Fong LG
Proc Natl Acad Sci U S A; 2007 Aug; 104(33):13432-7. PubMed ID: 17652517
[TBL] [Abstract][Full Text] [Related]
17. An accumulation of non-farnesylated prelamin A causes cardiomyopathy but not progeria.
Davies BS; Barnes RH; Tu Y; Ren S; Andres DA; Spielmann HP; Lammerding J; Wang Y; Young SG; Fong LG
Hum Mol Genet; 2010 Jul; 19(13):2682-94. PubMed ID: 20421363
[TBL] [Abstract][Full Text] [Related]
18. Site specificity determinants for prelamin A cleavage by the zinc metalloprotease ZMPSTE24.
Babatz TD; Spear ED; Xu W; Sun OL; Nie L; Carpenter EP; Michaelis S
J Biol Chem; 2021; 296():100165. PubMed ID: 33293369
[TBL] [Abstract][Full Text] [Related]
19. Requirements for efficient proteolytic cleavage of prelamin A by ZMPSTE24.
Barrowman J; Hamblet C; Kane MS; Michaelis S
PLoS One; 2012; 7(2):e32120. PubMed ID: 22355414
[TBL] [Abstract][Full Text] [Related]
20. Prelamin A and lamin A appear to be dispensable in the nuclear lamina.
Fong LG; Ng JK; Lammerding J; Vickers TA; Meta M; Coté N; Gavino B; Qiao X; Chang SY; Young SR; Yang SH; Stewart CL; Lee RT; Bennett CF; Bergo MO; Young SG
J Clin Invest; 2006 Mar; 116(3):743-52. PubMed ID: 16511604
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
